)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CollPlant Biotechnologies
CollPlant Biotechnologies (CLGN) investor relations material
CollPlant Biotechnologies Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary30 Sep, 2026
Executive summary
September acquisition of LightSolver expanded operations into photonic computing alongside regenerative medicine; June 30 financial results exclude LightSolver.
Regenerative medicine strategy remains focused on rhCollagen applications in medical aesthetics and 3D bioprinting, with strategic collaborations and commercialization as priorities.
Financial highlights
Q2 2026 revenue was $108K vs. $179K YoY; H1 revenue was $181K vs. $2.234M, including a non-recurring $2.0M milestone recognized in H1 2025.
Q2 gross loss was $456K vs. $7K; H1 gross loss was $699K vs. $1.860M gross profit, reflecting higher costs and lower facility utilization.
Q2 GAAP operating expenses fell to $2.2M from $3.2M; H1 fell to $5.0M from $6.7M, primarily from cost reductions.
Q2 GAAP net loss narrowed to $2.7M from $3.3M; H1 GAAP net loss widened to $5.8M from $4.8M.
H1 non-GAAP net loss was $5.4M vs. $3.9M; non-GAAP excludes share-based compensation and changes in operating lease accounts.
Outlook and guidance
Losses and negative operating cash flows are expected to continue until products reach commercial profitability; current resources are insufficient to fund operations for the next 12 months.
Planned funding sources include LightSolver commercialization, rhCollagen licensing and collaborations, additional equity or debt financing, and expense adjustments.
LightSolver remains in development; priorities include validating, scaling and commercializing its LPU technology while pursuing rhCollagen partnerships and out-licensing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CollPlant Biotechnologies
- AbbVie milestone revenue lifted FY2023 sales as regenerative programs advanced.CLGN
Q4 2023 - Milestone-driven optical computing acquisition targets $89B HPC market, scaling by 2028.CLGNInvestor update
- Registering resale of 31M shares; proceeds to company only from warrant exercises.CLGNRegistration filing
- Revenue dropped sharply in Q1 2026, but strategic initiatives and cost cuts advanced.CLGNQ1 2026
- Registering 3.3M shares for resale after partnership loss; focus shifts to core programs and cost cuts.CLGNRegistration filing
- 2025 revenue up 364% to $2.4M, net loss narrowed, and major R&D and IP milestones achieved.CLGNQ4 2025
- Plant-based rhCollagen platform powers next-gen regenerative products and global partnerships.CLGNCorporate presentation
- Q2 revenue dropped on no AbbVie milestone; cash reserves support implant and filler R&D.CLGNQ2 2024
- Revenue up, net loss down, and core regenerative programs advanced in Q1 2025.CLGNQ1 2025
Next CollPlant Biotechnologies earnings date
Q3 202625 Nov, 2026
CollPlant Biotechnologies
Next CollPlant Biotechnologies earnings date
Q3 202625 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on developing and commercializing products for tissue regeneration and organ manufacturing. The company utilizes its proprietary plant-based recombinant human collagen (rhCollagen) technology to create products that address unmet medical needs in various sectors, including wound care, orthopedics, and 3D bioprinting of tissues and organs. Key offerings include bioinks for 3D printing, wound care products, and orthobiologics. The company collaborates with industry partners to advance its innovative solutions and expand its market presence. The company is headquartered in Rehovot, Israel, and its shares are listed on the NASDAQ.